## JC14 Rec'd PCT/PTO 14 NOV 2005

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, PO. BOX 1450, ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, PO. BOX 1450, ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS. PO. BOX 1450, ON THE ABOVE DATE IN AN ENVELOP.

November

SDHOIDONOON A

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE AS DESIGNATED/ELECTED OFFICE

Applicants:

Biftu, et al.

Int. Appln. No:

PCT/US2004/014642

EXPRESS MAIL NO.

DATE OF DEPOSIT.

Int. Filing Date:

10 May 2004

US Appln. No.:

To Be Assigned

Case No.: 21404P

Art Unit:

Filed:

Concurrently Herewith

Examiner:

For:

3-AMINO-4-PHENYLBUTANOIC ACID

DERIVATIVES AS DIPEPTIDYL PEPTIDASE

INHIBITORS FOR THE TREATMENT OR

PREVENTION OF DIABETES

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to prosecution of the subject application. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Please amend this application as follows:

Amendments to the Specification are reflected on page 2 of this response.

Amendments to the Claims are reflected on page 3 of this response. Remarks begin on page 15 of this response.